{"name":"Md Mehedi Shahriar","slug":"md-mehedi-shahriar","ticker":"","exchange":"","domain":"","description":"Md Mehedi Shahriar is a pharmaceutical entity with a focus on the development and marketing of linaclotide formulations. The company currently has two marketed drugs, both of which are variations of linaclotide, targeting gastrointestinal disorders.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Linaclotide 145 micrograms","genericName":"Linaclotide 145 micrograms","slug":"linaclotide-145-micrograms","indication":"Other","status":"marketed"},{"name":"Linaclotide 72 micrograms","genericName":"Linaclotide 72 micrograms","slug":"linaclotide-72-micrograms","indication":"Chronic idiopathic constipation","status":"marketed"}]}],"pipeline":[{"name":"Linaclotide 145 micrograms","genericName":"Linaclotide 145 micrograms","slug":"linaclotide-145-micrograms","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Linaclotide 72 micrograms","genericName":"Linaclotide 72 micrograms","slug":"linaclotide-72-micrograms","phase":"marketed","mechanism":"Linaclotide is a guanylate cyclase-C (GC-C) agonist that increases intracellular cyclic GMP in intestinal epithelial cells, promoting fluid secretion and accelerating intestinal transit.","indications":["Chronic idiopathic constipation","Irritable bowel syndrome with constipation (IBS-C)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}